Prioritize indications for your asset

Compare indications using your team’s development criteria. Causaly combines scientific evidence, internal context and expert judgment to deliver a prioritized shortlist, with clear reasoning behind every recommendation.

Request a meeting

A shared approach across the asset lifecycle

The assessment evolves with your asset, from identifying diseases linked to a mechanism to selecting a development indication and evaluating expansion opportunities.

One base workflow across three indication decisions

Indication identification

Which indications should we pursue first?

Start from the target or mechanism and assess which diseases have a biological rationale strong enough to warrant further development.

Indication selection

Which indication should we commit to?

Bring the asset’s emerging evidence together with safety, feasibility, unmet need, and competitive context to compare the options for development.

Indication expansion

Where should we go next?

Use what is known about an existing or late-stage asset to assess additional indications and the evidence supporting each opportunity.

A prioritized shortlist with the reasoning attached

From candidate indications to a prioritized shortlist
Candidate indications

Comparative assessment

Compare each indication across three areas, using your team’s criteria and weighting.

Biological rationale

  • Assess how the mechanism is linked to the disease.
  • Evaluate whether the evidence supports a therapeutic approach.

Patient opportunity

  • Identify which patients could benefit.
  • Establish whether the rationale applies broadly or to a defined subgroup.

Barriers to development

  • Assess safety concerns and development feasibility.
  • Consider the competitive context and what could prevent progression.
Prioritized shortlist

What each recommendation means

Each indication is assigned one of four recommendations based on the evidence and your team’s criteria. These outcomes help your team decide where to commit resources, focus further research or stop pursuing an opportunity.

1

Prioritize

The evidence supports committing development resources to this indication, based on your team’s criteria.

2

Explore in a narrow segment

The evidence supports further assessment in a defined patient population. Focus research on the segment where the opportunity is most compelling.

3

Monitor / hypothesis only

The biology is promising, but the evidence is insufficient to support commitment. Keep the indication under review as new findings emerge.

4

Do not pursue

A specific disqualifying issue prevents the indication from meeting your team’s criteria. Review the rationale and supporting evidence behind its exclusion.

Review the evidence behind each recommendation

  • Understand the rationale

    See how scores were calculated and why indications were prioritized or excluded.

  • Examine the evidence

    Review supporting sources, contradictory findings and gaps in the evidence.

  • Distinguish evidence from inference

    See which findings are directly supported and where interpretation informs the recommendation.

Configured to how your team decides

Your organization’s method shapes the solution. Causaly’s PhD scientists work with your experts to define what the assessment covers, how evidence is weighed, and what the final output needs to contain.

  1. The starting point.

    Your asset or mechanism, development status, and any indications already under consideration.

  2. The decision criteria.

    The factors your team evaluates and the weight each carries.

  3. The scoring standard.

    What qualifies for each score, calibrated with your experts.

  4. The evidence sources.

    Published evidence and relevant internal data.

  5. The output format.

    The structure your scientific reviewers and governance committee expect.

Scientific Workflows encode the method. Agentic Research reasons across literature, Causaly’s knowledge graphs, and internal documents. Data Integration connects your proprietary evidence, while Professional Services supports configuration and ongoing refinement. Agent-to-agent integration enables workflows to run within your own infrastructure.

The solution is validated with your experts and maintained as evidence and organizational needs change.

Why use Causaly

Give your team a shared basis for comparing indications and explaining why some deserve investment while others need further evidence.

Configured to your decision.

Focus the assessment on the development decision your team needs to make.

A clear recommendation for every candidate.

Give your team a clear next step for each indication.

Built on your context.

Bring internal research, pipeline information, and prior decisions into the assessment alongside external evidence.

Ready for governance review.

Give reviewers a structured basis for challenging and discussing the assessment.

Read more

Article

Indication Expansion: What a Scientifically Rigorous Analysis Requires, and What It Can Leave Out

The biological rationale, counter-evidence, and traceability behind a rigorous assessment.

Article

How Causaly Solutions Support Portfolio Decisions

How configured scientific workflows support complex decisions across R&D.

Build a stronger case for your next indication decision

Discuss an asset your team is evaluating and see how Causaly can configure indication prioritization around your evidence, criteria, and review process.

Request a meeting